A Tiny Upstart Takes Aim at Robotic Surgery
Intuitive Surgical's (NASDAQ: ISRG) robots enjoy a near monopoly in hospitals, but that could change following last week's FDA approval of TransEnterix's (NYSEMKT: TRX) Senhance. Senhance is a robotic system that assists surgeons performing laparoscopic surgeries. It offers advantages, including haptic feedback, that could differentiate it from Intuitive Surgical's da Vinci system. Will TransEnterix carve out a meaningful slice of this fast-growing market?
Intuitive Surgical's ground-breaking da Vinci systems are reshaping laparoscopic surgery.
IMAGE SOURCE: TRANSENTERIX.
Source: Fool.com
Intuitive Surgical Inc Aktie
327,55 €
0,79 %
Starkes Buy-Sentiment bei Intuitive Surgical Inc mit 72 Buy- gegenüber 2 Sell-Einschätzungen.
Das Kursziel von 512 € für Intuitive Surgical Inc impliziert eine deutliche Steigerung um über 50% gegenüber 327.55 €.
